Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.Are you famous enough for picking great stocks to become a billionaire money manager? If not, then there's a lot you could learn from the handful of folks who have.It's easier than ever for individuals to invest alongside the professionals. The U.S. Securities and Exchange Commission makes anyone with more than $100 million under management report their activity to the public every three months. T ...

JHVEPhoto Overview Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether that storm. I previously covered PFE back in January and rated it a Strong Buy, and the total return since then has been mostly flat. Data by YCharts I wanted to take this opportunity to ...

Simfo/E+ via Getty Images Pfizer (NYSE:PFE)(NEOE:PFE:CA) has been a losing investment idea for several years, really since peak pandemic demand was reached for its leading COVID vaccines and antiviral prescription drugs. I have mentioned the stock several times as a strong income/yield proposition starting in 2022, with better than sector average valuations. Yet, the share quote has responded with flat to even lower pricing. My last bullish article was posted in December here. Finally, some stronger tra ...

16 abstracts feature new data and post-hoc analyses of pivotal trials across several types of hard-to-treat cancers TOKYO, May 13, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivot ...

Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. However, recent developments suggest a potential turnaround for the pharmaceutical giant. On May 1, 2024, Pfizer reported better-than-expected results for the first quarter of the year.Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Their non-GAAP earnings per share of $0.82 surpassed expectations by $0.31, while revenue of $1 ...

Pfizer stock currently has a 5.9% dividend yield, making it an attractive target for income investors.Pfizer (PFE -0.60%) stock has struggled over the past year, losing around 28% of its value. Its dividend payout, meanwhile, has continued to rise again and again. This combination has pushed the dividend yield up to nearly 6%. Is this your chance to secure a generous income stream of dividends?Earn $1,000 in dividend income with this strategyWith the current dividend yield at 5.9%, you would need to invest ...

These two blue chip dividend stocks are top buys right now.Dividends may be boring but are essential to building a well-balanced portfolio. After all, dividend payments have accounted for approximately 85% of the S&P 500's total returns since 1960, per a report by Hartford Funds.Which dividend stocks are worth buying in the current market? Telecom giant AT&T (T 0.18%) and pharmaceutical titan Pfizer (PFE 1.80%) scan as incredible bargains for long-term, income-oriented investors. Read on to find out more ab ...

Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years.After steadily raising its payout by 163% over the past 15 years, Pfizer (PFE 1.80%) continues to be one of the most reliable pharma stocks an income-seeking investor can reach for these days. The company is a pharmaceutical giant with many parts moving in different directions. Some of its blockbusters are losing market exclusivity, but it's also developing plenty of new drugs to take t ...

Financial Performance - Total revenues for the three months ended March 31, 2024, were $14,879 million, a decrease of 19% compared to $18,486 million for the same period in 2023[11]. - Product revenues for the same period were $12,443 million, down from $16,221 million, reflecting a decline of 23%[11]. - Alliance revenues increased to $2,172 million, compared to $2,060 million, marking a growth of 5%[11]. - Net income attributable to Pfizer Inc. common shareholders for the three months ended March 31, 2024, was $3,115 million, down from $5,543 million, a decrease of 44%[11]. - Earnings per share (EPS) for the three months ended March 31, 2024, were $0.55, compared to $0.98 for the same period in 2023, a decline of 44%[11]. - The company reported income from continuing operations before tax provision of $3,421 million, down from $6,270 million, a decrease of 45%[11]. - Comprehensive income attributable to Pfizer Inc. for the three months ended March 31, 2024, was $3,319 million, down from $5,558 million for the same period in 2023[13]. - Net income for the three months ended March 31, 2024, was $3,123 million, a decrease of 44% compared to $5,556 million for the same period in 2023[13]. Expenses and Costs - Research and development expenses for the quarter were $2,493 million, slightly down from $2,505 million in the prior year[11]. - Cost of sales for the quarter was $3,379 million, a decrease from $4,886 million, reflecting a reduction of 31%[11]. - Amortization of intangible assets for the quarter was $1,308 million, up from $1,103 million, an increase of 19%[11]. - The company incurred restructuring charges and certain acquisition-related costs amounting to $102 million, compared to $9 million in the same period last year[11]. - The company reported depreciation and amortization expenses of $1,736 million for the three months ended March 31, 2024, an increase from $1,487 million in the prior year[18]. Assets and Liabilities - Total current assets decreased to $42,415 million as of March 31, 2024, down from $43,333 million at December 31, 2023[14]. - Total liabilities decreased to $128,537 million as of March 31, 2024, compared to $137,213 million at December 31, 2023[14]. - Cash and cash equivalents significantly decreased to $719 million from $2,853 million at December 31, 2023[14]. - Trade accounts receivable decreased to $10,989 million as of March 31, 2024, from $11,566 million at December 31, 2023[14]. - Total equity attributable to Pfizer Inc. shareholders increased to $92,282 million as of March 31, 2024, from $89,014 million at December 31, 2023[14]. - The company reported a decrease in inventories to $10,892 million as of March 31, 2024, compared to $10,189 million at December 31, 2023[14]. - Short-term borrowings decreased to $8,232 million as of March 31, 2024, from $10,350 million at December 31, 2023[14]. - The company’s long-term debt remained relatively stable at $61,307 million as of March 31, 2024, compared to $61,538 million at December 31, 2023[14]. Cash Flow - Net cash provided by operating activities for the three months ended March 31, 2024, was $1,090 million, down from $1,212 million in the same period last year[18]. - The company reported a net cash increase from investing activities of $1,732 million for the three months ended March 31, 2024, compared to $3,315 million in the prior year[18]. - Cash dividends paid during the three months ended March 31, 2024, were $2,372 million, compared to $2,303 million in the same period last year[18]. Acquisitions and Investments - Pfizer completed the acquisition of Seagen for a total consideration of $44.2 billion, with the acquisition date on December 14, 2023[26]. - The provisional amount recognized for identifiable intangible assets from the Seagen acquisition was $7,970 million, subject to adjustments[27]. - Goodwill recognized from the Seagen acquisition was $17,650 million after measurement period adjustments[28]. - Pfizer sold approximately 30% of its investment in Haleon for total consideration of $3.5 billion, recognizing a gain of $150 million in the first quarter of 2024[31]. - The carrying value of Pfizer's investment in Haleon decreased to $7,922 million as of March 31, 2024, down from $10,980 million as of April 2, 2023[35]. Legal Proceedings - The company is involved in various legal proceedings, including patent litigation, which could result in significant revenue loss if adverse outcomes occur[87]. - Pfizer is currently facing challenges to its patent rights in multiple jurisdictions, which could impact the market entry of generic products[88]. - The company has settled several patent-infringement actions related to Xeljanz with generic manufacturers, with ongoing litigation against Sinotherapeutics[90]. - Several generic companies have filed ANDAs with the FDA for Mektovi, challenging multiple patents expiring between 2030 and 2033, leading to patent infringement actions by the company[91]. - In June 2023, the company initiated patent infringement actions against Teva Pharmaceuticals regarding Mektovi, asserting the validity of three patents[91]. - Multiple generic companies have filed ANDAs for tafamidis and tafamidis meglumine, prompting the company and Scripps Research Institute to file patent infringement actions in August 2023[92]. - The company is involved in various legal proceedings regarding Comirnaty, including multiple complaints alleging patent infringement filed by Alnylam and Moderna, with ongoing litigation in both U.S. and European courts[94][95]. Revenue Breakdown - Biopharma segment revenues for Q1 2024 were $14,604 million, a decrease of 19% from $18,173 million in Q1 2023[129]. - U.S. revenues increased by 9% to $9,514 million in Q1 2024, compared to $8,711 million in Q1 2023[131]. - Revenues from international developed markets fell by 43% to $3,198 million, while emerging markets dropped by 48% to $2,167 million[131]. - Significant product revenues included $2,035 million from Paxlovid in Q1 2024, down from $4,069 million in Q1 2023[133]. - Oncology division revenue increased to $2,572 million in Q1 2024 from $1,983 million in Q1 2023, marking a growth of about 30%[136]. - Revenue from Oxbryta for sickle cell disease rose to $84 million in Q1 2024, up from $71 million in Q1 2023, reflecting a growth of about 18%[136]. - Revenue from Cibinqo for atopic dermatitis increased to $42 million in Q1 2024, compared to $16 million in Q1 2023, showing a significant growth of 163%[136]. - Total royalty revenues increased to $263 million in Q1 2024 from $204 million in Q1 2023, representing a growth of approximately 29%[136].

Pfizer has agreed to settle more than 10,000 lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.The lawsuits were filed in state courts across the country, but the agreements don’t completely resolve Pfizer’s exposure to the claims linking Zantac and cancer, according to Bloomberg News.Terms of the settlements were not disclosed. The Post has sought comment from Pfizer. 3 Pfizer has reportedly agreed to settle more tha ...